Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients

surveillance program, 1998–1999. Antimicrobial Agents and Che-motherapy 46, 879–81.7. Bell, J. M., Turnidge, J. D. & Jones, R. N. (2002). Antimicrobialresistance trends in community-acquired respiratory tract pathogens inthe Western Pacic Region and South Africa: report from the SENTRYantimicrobial surveillance program, (1998–1999) including an in vitroevaluation of BMS284756. International Journal of Antimicrobial Agents19, 125–32.8. National Committee for Clinical Laboratory Standards. (2003).Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria thatGrow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS,Wayne, PA, USA.9. Hasegawa, K., Chiba, N., Kobayashi, R. et al. (2004). Rapidlyincreasing prevalence of b-lactamase-nonproducing, ampicillin-resist-ant Haemophilus inuenzae type b in patients with meningitis.Antimicrobial Agents and Chemotherapy 48, 1509–14.10. Gross, M., Clements, J., Beckett, R. P. et al. (2004). Oral anti-pneumococcal activity and pharmacokinetic proling of a novel peptidedeformylase inhibitor. Journal of Antimicrobial Chemotherapy 53,487–93.11. Loand, D., Difuntorum, S., Waller, A. et al. (2004). In vitroantibacterial activity of the peptide deformylase inhibitor BB-83698.Journal of Antimicrobial Chemotherapy 53, 664–8.